- Home
- EBF vs CELC Comparison
EBF vs CELC Comparison
Compare EBF & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBF
- CELC
- Stock Information
- Founded
- EBF 1909
- CELC 2011
- Country
- EBF United States
- CELC United States
- Employees
- EBF N/A
- CELC N/A
- Industry
- EBF Office Equipment/Supplies/Services
- CELC Medical Specialities
- Sector
- EBF Consumer Discretionary
- CELC Health Care
- Exchange
- EBF Nasdaq
- CELC Nasdaq
- Market Cap
- EBF 488.0M
- CELC 440.0M
- IPO Year
- EBF N/A
- CELC 2017
- Fundamental
- Price
- EBF $18.66
- CELC $13.79
- Analyst Decision
- EBF
- CELC Strong Buy
- Analyst Count
- EBF 0
- CELC 6
- Target Price
- EBF N/A
- CELC $30.67
- AVG Volume (30 Days)
- EBF 153.4K
- CELC 204.8K
- Earning Date
- EBF 06-23-2025
- CELC 08-13-2025
- Dividend Yield
- EBF 5.38%
- CELC N/A
- EPS Growth
- EBF N/A
- CELC N/A
- EPS
- EBF 1.51
- CELC N/A
- Revenue
- EBF $388,707,000.00
- CELC N/A
- Revenue This Year
- EBF $1.15
- CELC N/A
- Revenue Next Year
- EBF N/A
- CELC N/A
- P/E Ratio
- EBF $12.36
- CELC N/A
- Revenue Growth
- EBF N/A
- CELC N/A
- 52 Week Low
- EBF $17.15
- CELC $7.58
- 52 Week High
- EBF $25.75
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- EBF 50.55
- CELC 61.43
- Support Level
- EBF $18.07
- CELC $12.48
- Resistance Level
- EBF $18.74
- CELC $13.60
- Average True Range (ATR)
- EBF 0.36
- CELC 0.73
- MACD
- EBF 0.00
- CELC 0.07
- Stochastic Oscillator
- EBF 55.14
- CELC 83.66
About EBF Ennis Inc.
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialities, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360º Custom LabelsSM, ColorWorx, Enfusion, among others.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.